Abstract
Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis. The reemergence of tuberculosis as a potential public health threat, the high susceptibility of human immunodeficiency virus-infected persons to the disease, and the proliferation of multi-drug-resistant strains have created a need for the development of new antimycobacterial agents. Mycolic acids, the hallmark of mycobacteria, are high-molecularweight α-alkyl, β-hydroxy fatty acids, which appear mostly as bound esters in the mycobacterial cell wall. The product of the M. tuberculosis inhA structural gene (InhA) has been shown to be the primary target for isoniazid (INH), the most prescribed drug for active TB and prophylaxis. InhA was identified as an NADH-dependent enoyl-ACP reductase specific for long-chain enoyl thioesters. InhA is a member of the mycobacterial Type II fatty acid biosynthesis system, which elongates acyl fatty acid precursors of mycolic acids. Although the history of chemotherapeutic agent development demonstrates the remarkably successful tinkering of a few structural scaffolds, it also emphasizes the ongoing, cyclical need for innovation. The main focus of our contribution is on new data describing the rationale for the design of a pentacyano( isoniazid)ferrateII compound that requires no KatG-activation, its chemical characterization, in vitro activity studies against WT and INH-resistant I21V M. tuberculosis enoyl reductases, the slow-onset inhibition mechanism of WT InhA by the inorganic complex, and molecular modeling of its interaction with WT InhA. This inorganic complex represents a new class of lead compounds to the development of anti-tubercular agents aiming at inhibition of a validated target.
Keywords: Tuberculosis, mycolic acids, enoyl reductase, InhA, isoniazid, inhibitors, inorganic complex, molecular modeling
Current Pharmaceutical Design
Title: Slow-Onset Inhibition of 2-trans-Enoyl-ACP (CoA) Reductase from Mycobacterium tuberculosis by an Inorganic Complex
Volume: 12 Issue: 19
Author(s): Jaim S. Oliveira, Eduardo H.S. de Sousa, Osmar N. de Souza, lcaro S. Moreira, Diogenes S. Santos and Luiz A. Basso
Affiliation:
Keywords: Tuberculosis, mycolic acids, enoyl reductase, InhA, isoniazid, inhibitors, inorganic complex, molecular modeling
Abstract: Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis. The reemergence of tuberculosis as a potential public health threat, the high susceptibility of human immunodeficiency virus-infected persons to the disease, and the proliferation of multi-drug-resistant strains have created a need for the development of new antimycobacterial agents. Mycolic acids, the hallmark of mycobacteria, are high-molecularweight α-alkyl, β-hydroxy fatty acids, which appear mostly as bound esters in the mycobacterial cell wall. The product of the M. tuberculosis inhA structural gene (InhA) has been shown to be the primary target for isoniazid (INH), the most prescribed drug for active TB and prophylaxis. InhA was identified as an NADH-dependent enoyl-ACP reductase specific for long-chain enoyl thioesters. InhA is a member of the mycobacterial Type II fatty acid biosynthesis system, which elongates acyl fatty acid precursors of mycolic acids. Although the history of chemotherapeutic agent development demonstrates the remarkably successful tinkering of a few structural scaffolds, it also emphasizes the ongoing, cyclical need for innovation. The main focus of our contribution is on new data describing the rationale for the design of a pentacyano( isoniazid)ferrateII compound that requires no KatG-activation, its chemical characterization, in vitro activity studies against WT and INH-resistant I21V M. tuberculosis enoyl reductases, the slow-onset inhibition mechanism of WT InhA by the inorganic complex, and molecular modeling of its interaction with WT InhA. This inorganic complex represents a new class of lead compounds to the development of anti-tubercular agents aiming at inhibition of a validated target.
Export Options
About this article
Cite this article as:
Oliveira S. Jaim, de Sousa H.S. Eduardo, de Souza N. Osmar, Moreira S. lcaro, Santos S. Diogenes and Basso A. Luiz, Slow-Onset Inhibition of 2-trans-Enoyl-ACP (CoA) Reductase from Mycobacterium tuberculosis by an Inorganic Complex, Current Pharmaceutical Design 2006; 12 (19) . https://dx.doi.org/10.2174/138161206777698927
DOI https://dx.doi.org/10.2174/138161206777698927 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Functionalization of Coumarin-Pyrazole Scaffold: Recent Development, Challenges, and Opportunities
Current Organic Synthesis Editorial (Thematic Issue: Small Molecule Drug Discovery for Pediatric Diseases)
Mini-Reviews in Medicinal Chemistry The Activity of Alkanna Species in vitro Culture and Intact Plant Extracts Against Antibiotic Resistant Bacteria
Current Pharmaceutical Design Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science Potential Therapeutic Agents from the Red Sea Organisms
Medicinal Chemistry COVID-19/Any Respiratory Pandemic- What a Radiology Resident Must Know and Report
Current Medical Imaging New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry Predicting Drugs and Proteins in Parasite Infections with Topological Indices of Complex Networks: Theoretical Backgrounds, Applications and Legal Issues
Current Pharmaceutical Design New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Current Medicinal Chemistry Appropriate Antibiotic Prescribing Pattern in Hospitalized Children
Current Drug Safety Computational Analysis to Predict Drug Targets for the Therapeutic Management of <i>Mycobacterium avium</i> sub. <i>Paratuberculosis</i>
Current Drug Discovery Technologies Diabetic Pneumopathy- A Novel Diabetes-associated Complication: Pathophysiology, the Underlying Mechanism and Combination Medication
Endocrine, Metabolic & Immune Disorders - Drug Targets Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine Current Understanding of Interactions between Nanoparticles and ABC Transporters in Cancer Cells
Current Medicinal Chemistry QSAR and Docking Studies of HCV NS3 Serine Protease Inhibitors
Medicinal Chemistry Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19
Infectious Disorders - Drug Targets Investigation of the Antimycobacterial Activity of 8-hydroxyquinolones
Medicinal Chemistry